JP7793614B2 - チアジアゾロン誘導体と、それらの糖尿病および関連疾患の治療のためのampkアゴニストとしての使用 - Google Patents

チアジアゾロン誘導体と、それらの糖尿病および関連疾患の治療のためのampkアゴニストとしての使用

Info

Publication number
JP7793614B2
JP7793614B2 JP2023520459A JP2023520459A JP7793614B2 JP 7793614 B2 JP7793614 B2 JP 7793614B2 JP 2023520459 A JP2023520459 A JP 2023520459A JP 2023520459 A JP2023520459 A JP 2023520459A JP 7793614 B2 JP7793614 B2 JP 7793614B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
compounds
formula
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023520459A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023543924A (ja
JP2023543924A5 (cg-RX-API-DMAC7.html
Inventor
トーマス エドランド
ジェイコブ ウェストマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betagenon AB
Original Assignee
Betagenon AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betagenon AB filed Critical Betagenon AB
Publication of JP2023543924A publication Critical patent/JP2023543924A/ja
Publication of JP2023543924A5 publication Critical patent/JP2023543924A5/ja
Application granted granted Critical
Publication of JP7793614B2 publication Critical patent/JP7793614B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C07F9/65392—Five-membered rings containing two nitrogen atoms
    • C07F9/65397—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023520459A 2020-10-01 2021-09-30 チアジアゾロン誘導体と、それらの糖尿病および関連疾患の治療のためのampkアゴニストとしての使用 Active JP7793614B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2015585.9A GB202015585D0 (en) 2020-10-01 2020-10-01 New compounds
GB2015585.9 2020-10-01
PCT/GB2021/052535 WO2022069894A1 (en) 2020-10-01 2021-09-30 Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders

Publications (3)

Publication Number Publication Date
JP2023543924A JP2023543924A (ja) 2023-10-18
JP2023543924A5 JP2023543924A5 (cg-RX-API-DMAC7.html) 2024-10-04
JP7793614B2 true JP7793614B2 (ja) 2026-01-05

Family

ID=73223766

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023520459A Active JP7793614B2 (ja) 2020-10-01 2021-09-30 チアジアゾロン誘導体と、それらの糖尿病および関連疾患の治療のためのampkアゴニストとしての使用

Country Status (13)

Country Link
US (1) US12643918B2 (cg-RX-API-DMAC7.html)
EP (1) EP4222147B1 (cg-RX-API-DMAC7.html)
JP (1) JP7793614B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230079163A (cg-RX-API-DMAC7.html)
CN (1) CN116368141B (cg-RX-API-DMAC7.html)
AU (1) AU2021352146A1 (cg-RX-API-DMAC7.html)
CA (1) CA3193947A1 (cg-RX-API-DMAC7.html)
ES (1) ES3018732T3 (cg-RX-API-DMAC7.html)
GB (1) GB202015585D0 (cg-RX-API-DMAC7.html)
HU (1) HUE071685T2 (cg-RX-API-DMAC7.html)
MX (1) MX2023003825A (cg-RX-API-DMAC7.html)
PL (1) PL4222147T3 (cg-RX-API-DMAC7.html)
WO (1) WO2022069894A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3075388T3 (en) 2019-10-18 2026-08-04 Betagenon Ab New formulations
GB202015585D0 (en) 2020-10-01 2020-11-18 Betagenon Bio Ab New compounds
GB202112529D0 (en) * 2021-09-02 2021-10-20 Betagenon Bio Ab New compounds
JPWO2024075784A1 (cg-RX-API-DMAC7.html) * 2022-10-05 2024-04-11

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004162A2 (en) 2009-07-08 2011-01-13 Betagenon Ab Compounds useful as medicaments
WO2013108026A1 (en) 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
WO2020095010A1 (en) 2018-11-05 2020-05-14 Balticgruppen Bio Ab Methods of treating diabetes in severe insulin-resistant diabetic subjects

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201915094D0 (en) 2019-10-18 2019-12-04 Balticgruppen Bio Ab New formulations
ES3075388T3 (en) 2019-10-18 2026-08-04 Betagenon Ab New formulations
GB202015585D0 (en) 2020-10-01 2020-11-18 Betagenon Bio Ab New compounds
GB202100352D0 (en) 2021-01-12 2021-02-24 Balticgruppen Bio Ab New methods
GB202112529D0 (en) 2021-09-02 2021-10-20 Betagenon Bio Ab New compounds
CN122421964A (zh) 2023-07-20 2026-07-17 塔吉农有限责任公司 使用双重ampk激活剂和线粒体解偶联剂调节血糖水平的方法
JP2026526085A (ja) 2023-07-20 2026-08-05 ベタゲノン アーベー 代謝非柔軟性により誘発される心筋症の治療方法
CN121925257A (zh) 2023-08-03 2026-04-24 塔吉农有限责任公司 用pdk抑制剂4-氯-n-(2-(4-氯苄基)-3-氧代-2,3-二氢-1,2,4-噻二唑-5-基)苯甲酰胺治疗癌症
WO2025252672A1 (en) 2024-06-03 2025-12-11 Betagenon Ab Use of tryptophan and metabolites thereof as biomarkers for treatment methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004162A2 (en) 2009-07-08 2011-01-13 Betagenon Ab Compounds useful as medicaments
WO2013108026A1 (en) 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
WO2020095010A1 (en) 2018-11-05 2020-05-14 Balticgruppen Bio Ab Methods of treating diabetes in severe insulin-resistant diabetic subjects

Also Published As

Publication number Publication date
ES3018732T3 (en) 2025-05-19
GB202015585D0 (en) 2020-11-18
MX2023003825A (es) 2023-06-06
PL4222147T3 (pl) 2025-06-09
EP4222147B1 (en) 2025-03-19
CN116368141A (zh) 2023-06-30
HUE071685T2 (hu) 2025-09-28
JP2023543924A (ja) 2023-10-18
CA3193947A1 (en) 2022-04-07
KR20230079163A (ko) 2023-06-05
AU2021352146A1 (en) 2023-06-01
US12643918B2 (en) 2026-06-02
WO2022069894A1 (en) 2022-04-07
EP4222147A1 (en) 2023-08-09
EP4222147C0 (en) 2025-03-19
US20230382930A1 (en) 2023-11-30
CN116368141B (zh) 2025-09-23

Similar Documents

Publication Publication Date Title
CN116368141B (zh) 噻二唑酮衍生物及其作为ampk激动剂用于治疗糖尿病和相关疾病的用途
EP4125896B1 (en) Treatment of type 2 diabetes with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
EP4507691A2 (en) Jak inhibitor analogs, formulations, and uses thereof
US20230109134A1 (en) Pyridazinone or pyridazine compound and derivative and pharmaceutical composition thereof
JP2023096079A (ja) 化合物の製剤およびそれらの使用
JP2014512399A (ja) ナトリウム依存性グルコース輸送タンパク質阻害剤並びにその調製方法及び使用
JP2017537954A (ja) 2−(tert−ブチルアミノ)−4−((1R,3R,4R)−3−ヒドロキシ−4−メチルシクロヘキシルアミノ)−ピリミジン−5−カルボキサミドの製剤
KR20210102887A (ko) 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
US20250136563A1 (en) Thiadiazolone derivatives useful as ampk activator
JP2024516040A (ja) キサンチンオキシダーゼ抑制剤
EP4585593A1 (en) Polymorph of glp-1r agonist compound, preparation method therefor, and use thereof
JP2025525586A (ja) 器官の疾患または障害をask1阻害剤で処置する方法
US12522628B2 (en) Aryl glucoside derivative and use thereof in drug
KR102730711B1 (ko) 피리미딘-5-카르복스아미드 화합물
HK40092998A (en) Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders
HK40092998B (en) Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders
US20230331761A1 (en) Aryl Glucoside Derivative, Preparation Method Therefor And Application Thereof
WO2011002011A1 (ja) Sglt1阻害薬とdpp-iv阻害薬を組み合わせてなる医薬
CN106432026A (zh) 一类对糖尿病具有潜在治疗活性的化合物
US12612426B2 (en) Aryl glucoside derivative
WO2010098298A1 (ja) 栄養素の消化吸収抑制作用を有する化合物とシクロヘキサンカルボキサミド誘導体を組み合わせてなる医薬組成物
WO2025099561A1 (en) Oral controlled-release matrix formulations of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
KR20190090729A (ko) 토파시티닙의 신규 염, 이의 제조방법 및 이를 포함하는 약학 조성물
WO2025237355A1 (zh) 一种glp-1受体激动剂化合物、其制备方法及其应用
HK40122633A (en) Jak inhibitor analogs, formulations, and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240924

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240924

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20250205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251118

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251217

R150 Certificate of patent or registration of utility model

Ref document number: 7793614

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150